A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients.

ABSTRACT: To evaluate the pharmacokinetic effects of SHR3680 on repaglinide and bupropion and its metabolite hydroxybupropion.

Methods

A single-centre, open-label, single-arm, fixed-sequence clinical trial in 18 patients with prostate cancer.

Results

After a single oral dose of 0.5 mg repaglinide and SHR3680, geometric mean peak plasma concentration (C_max ) of plasma repaglinide was 14.240 and 5.887 ng/mL, geometric mean area under the concentration-time curve (AUC_0-t )was 20.577 and 7.320 h ng/mL, geometric mean AUC_0-∞ was 20.949 and 7.451 h ng/mL, mean half-life (t_1/2 ) was 1.629 and 1.195 hours, and geometric mean oral clearance (CL/F) was 23.867 and 67.107 L/h, respectively. After a single oral administration of 150 mg bupropion and SHR36

SUBMITTER: Dai T 

PROVIDER: S-EPMC10092624 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature